Medline Inc. (MDLN) Q3 2026 Earnings Call Transcript

Medline's Q3 2026 net sales rose 10.4% to $7.9B and adjusted EBITDA increased 11.8% to $1.0B; management raised full-year organic sales growth guidance to 10%-10.5% from 9%-10%, while reaffirming adjusted EBITDA guidance of $3.3B-$3.4B. Free cash flow was $1.8B for the first nine months, net leverage fell to 2.5x from 2.9x in the prior quarter, and the company authorized a $1B share repurchase program and prepaid $750M of term debt. Inflation and mix are pressuring margins, with management estimating $80M of 2026 Middle East-related costs and projecting low-to-mid-single-digit adjusted EBITDA growth in 2027 as it invests in operations and quality.

Analysis

The key issue is growth quality, not demand: new prime-vendor contracts are bringing in lower-margin distribution revenue and first-year rebates, while the higher-margin benefit depends on converting those customers to Medline-branded products over time. That makes current sales momentum a weak proxy for near-term earnings power. The conversion thesis is credible but execution-dependent; verify cohort-level brand penetration and SCS margin recovery rather than extrapolating signings.

Near term, higher-cost inventory flowing through COGS and elevated freight, diesel, and materials costs create downside risk to margins even if sales hold up. Tariff refunds and favorable working capital also flatter cash generation, so neither should be treated as a recurring earnings or cash-flow run rate. For 2027, management’s slower EBITDA growth than sales is consistent with the cost and investment burden; the 2028 operating-leverage promise is conditional, not yet an earnings catalyst. The multiyear quality review adds a tail risk of further remediation or product exits, though one product decision does not establish a broader pattern. New distribution capacity can support share gains, but weak utilization would delay returns.

Contrarian read: the buyback authorization is not a floor or proof of undervaluation; capital also has competing calls from debt reduction, facilities, quality work, and acquisitions. With no valuation or price data here, the quarter supports a watchlist stance more than an unconditional chase. The thesis improves if customer conversions lift SCS margins without sacrificing renewals; it weakens if inflation persists, pricing is insufficient, or quality costs expand.

Key Decisions for Investors

• MDLN: Avoid chasing the headline growth. Consider a staged long only on post-earnings weakness if subsequent reporting shows SCS margin stabilization and continued customer implementations; upside would come from durable growth plus later conversion-led margin lift, while the principal downside is earnings lagging sales as costs and rebates persist.
• Track quarterly SCS adjusted EBITDA margin, brand-conversion rates in newly implemented accounts, and net pricing versus COGS inflation. Reassess the long thesis if SCS margins keep falling or management reduces its 2027 earnings framework.
• Treat the buyback and recent cash generation as secondary positives, not a valuation signal: verify repurchase execution, working-capital normalization, and tariff-refund treatment in reported cash flow. Monitor quality-plan updates for additional remediation, recalls, or portfolio exits.